| Literature DB >> 35721423 |
Tasnim Hasan1,2, Pham Ngoc Thach3, Nguyen Thu Anh2, Le Thi Thu Hien2, Nguyen Thi Mai An4, Dang Thi Thuy3, Le Van Duyet3, Nguyen Thi Dung5, Tran Thi Diep5, Hoang Van Huynh6, Brett G Toelle1,2,7, Guy B Marks2,8, Greg J Fox1,2.
Abstract
Objective: The aim of this study was to determine the seroprevalence of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) antibodies in high-risk communities and quarantine workers in Vietnam.Entities:
Year: 2021 PMID: 35721423 PMCID: PMC8665841 DOI: 10.1016/j.ijregi.2021.12.001
Source DB: PubMed Journal: IJID Reg ISSN: 2772-7076
Characteristics of participants and sero-positivity for SARS-CoV-2 antibodies in two sub-communes affected by COVID-19
| Characteristics | Bac Ma 1 sub-commune | Tien sub-commune |
|---|---|---|
| Total participants | 897 | 1172 |
| Age, years (median, interquartile range) | 42 (19–57) | 37 (20–53) |
| Female gender | 479 (53.4) | 501 (42.7) |
| Number of PCR-confirmed COVID-19 cases in community | 7 | 18 |
| Period of outbreak (time between diagnosis of first and last case) | Jan 27 to Feb 6, 2021 | Feb 7–27, 2021 |
| Time from the last case diagnosed to serological testing (weeks) | 11.9 | 8.9 |
| Sero-positivity for SARS-CoV-2 | ||
| Total | 1/897 (0.1) | 5/1172 (0.4) |
| Household contacts | 0/7 (0.0) | 2/22 (9.1) |
| Close contacts | 0/14 (0.0) | 1/18 (5.6) |
| Community members | 1/876 (0.1) | 1/920 (0.1) |
| Migrant worker | 0/0 (0.0) | 1/212 (0.4) |
| Occupation | ||
| Student* | 223 (24.9) | 217 (18.5) |
| Office worker | 20 (2.2) | 22 (1.9) |
| Factory worker | 100 (11.1) | 318 (27.1) |
| Farmer | 318 (35.5) | 89 (7.6) |
| Self-employed | 107 (11.9) | 156 (13.3) |
| Retired | 58 (6.5) | 43 (36.7) |
| Unemployed | 2 (0.2) | 4 (0.3) |
| Healthcare worker | 3 (0.3) | 4 (0.3) |
| Tourist | 0 (0.0) | 1 (0.1) |
| Overseas students, returning home | 0 (0.0) | 0 (0.0) |
| People returning home | 1 (0.1) | 0 (0.0) |
| Service workers | 14 (1.6) | 13 (1.1) |
| Other | 52 (6.8) | 54 (4.6) |
| Comorbidities | ||
| Diabetes | 31 (3.5) | 26 (2.2) |
| Hypertension | 88 (22.2) | 75 (6.4) |
| Renal disease | 25 (2.8) | 8 (0.7) |
| Heart disease | 33 (3.7) | 22 (1.9) |
| Pulmonary disease | 10 (1.1) | 8 (0.7) |
| Immunological disease | 2 (0.2) | 1 (0.1) |
| Smoker | 111 (12.4) | 100 (8.5) |
| Symptoms during period of outbreak | ||
| Fever | 3 (0.3) | 4 (0.3) |
| Cough | 6 (0.7) | 15 (12.8) |
| Sputum production | 7 (0.8) | 5 (0.4) |
| Hemoptysis | 0 (0.0) | 0 (0.0) |
| Dyspnea | 7 (0.8) | 3 (0.3) |
| Sore throat | 11 (12.3) | 28 (2.4) |
| Nasal discharge | 13 (14.5) | 31 (2.6) |
| Headache | 21 (23.4) | 33 (2.8) |
| Anosmia | 0 (0.0) | 0 (0.0) |
| Diarrhea | 3 (3.3) | 1 (0.1) |
| Fatigue | 8 (8.9) | 21 (1.8) |
| Myalgia | 5 (5.6) | 10 (0.8) |
| Chills | 0 (0.0) | 1 (0.1) |
| Conjunctivitis | 3 (3.3) | 1 (0.1) |
| Other | 8 (8.9) | 14 (1.2) |
PCR: polymerase chain reaction
Characteristics of study participants and sero-positivity for SARS-CoV-2 among workers in two quarantine facilities
| Characteristics | Healthcare workers (HCW) | Logistic and security staff | Specimen collectors | Total |
|---|---|---|---|---|
| Number of participants | 15 | 11 | 24 | 50 |
| Age, years (median, interquartile range) | 32 (27–34) | 37 (32–50) | 30 (26–32) | 31 (26–35) |
| Female gender | 13 (86.7) | 2 (18.2) | 23 (95.8) | 38 (76.0) |
| Number of PCR-confirmed COVID-19 cases diagnosed among quarantined contacts in facilities | 16 | |||
| Period of quarantine of positive COVID-19 cases at the facilities | Jan 30 to Feb 23 | |||
| Stayed onsite at facility | Yes | Yes | No | |
| Length of stay at facility (median, interquartile range) | 44 (22–64) days | 46 (30–69) days | NA | 44 (23–69) days |
| Time from the last case diagnosed to serological testing | 9.1 weeks | |||
| Sero-positivity | 1/15 (6.7) | 0/11 (0.0) | 0/24 (0.0) | 1/50 (2.0) |
| Comorbidities | ||||
| Diabetes | 0/15 (0.0) | 0/11 (0.0) | 0/24 (0.0) | 0/50 (0.0) |
| Hypertension | 0/15 (0.0) | 1/11 (9.1) | 0/24 (0.0) | 1/50 (2.0) |
| Renal disease | 0/15 (0.0) | 0/11 (0.0) | 0/24 (0.0) | 0/50 (0.0) |
| Heart disease | 0/15 (0.0) | 0/11 (0.0) | 1/24 (4.2) | 1/50 (2.0) |
| Pulmonary disease | 0/15 (0.0) | 1/11 (9.1) | 0/24 (0.0) | 1/50 (2.0) |
| Immunological disease | 0/15 (0.0) | 0/11 (0.0) | 0/24 (0.0) | 0/50 (0.0) |
| Symptoms during the period working at the center | ||||
| Fever | 0/15 (0.0) | 0/11 (0.0) | 0/24 (0.0) | 0/50 (0.0) |
| Cough | 0/15 (0.0) | 1/11 (9.1) | 0/24 (0.0) | 1/50 (2.0) |
| Sputum production | 0/15 (0.0) | 0/11 (0.0) | 0/24 (0.0) | 0/50 (0.0) |
| Hemoptysis | 0/15 (0.0) | 0/11 (0.0) | 0/24 (0.0) | 0/50 (0.0) |
| Dyspnea | 0/15 (0.0) | 0/11 (0.0) | 0/24 (0.0) | 0/50 (0.0) |
| Sore throat | 0/15 (0.0) | 1/11 (9.1) | 0/24 (0.0) | 1/50 (2.0) |
| Nasal discharge | 0/15 (0.0) | 0/11 (0.0) | 0/24 (0.0) | 0/50 (0.0) |
| Headache | 1/15 (6.7) | 1/11 (9.1) | 1/24 (4.2) | 3/50 (6.0) |
| Anosmia | 0/15 (0.0) | 0/11 (0.0) | 0/24 (0.0) | 0/50 (0.0) |
| Diarrhoea | 0/15 (0.0) | 0/11 (0.0) | 0/24 (0.0) | 0/50 (0.0) |
| Fatigue | 0/15 (0.0) | 0/11 (0.0) | 0/24 (0.0) | 0/50 (0.0) |
| Myalgia | 0/15 (0.0) | 0/11 (0.0) | 0/24 (0.0) | 0/50 (0.0) |
| Chills | 0/15 (0.0) | 0/11 (0.0) | 0/24 (0.0) | 0/50 (0.0) |
| Conjunctivitis | 0/15 (0.0) | 0/11 (0.0) | 0/24 (0.0) | 0/50 (0.0) |
| Other | 0/15 (0.0) | 0/11 (0.0) | 0/24 (0.0) | 0/50 (0.0) |
PCR: polymerase chain reaction